Functionalized Cerium Dioxide Nanoparticles with Antioxidative Neuroprotection for Alzheimer’s Disease

References

• Liu R, Yang J, Liu L, et al. An “Amyloid-β Cleaner” for the treatment of Alzheimer’s disease by normalizing microglial dysfunction. Adv Sci. 2020;7(2):1901555. doi:10.1002/advs.201901555
   Web of Science ®Google Scholar
• Sun J, Wei C, Liu Y, et al. Progressive release of mesoporous nano-selenium delivery system for the multi-channel synergistic treatment of Alzheimer’s disease. Biomaterials. 2019;197:417–431. doi:10.1016/j.biomaterials.2018.12.027
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Boyd-Kimball D. Oxidative stress, Amyloid-β peptide, and altered key molecular pathways in the pathogenesis and progression of Alzheimer’s disease. J Alzheimers Dis. 2018;62(3):1345–1367. doi:10.3233/JAD-170543
   PubMed Web of Science ®Google Scholar
• Bai R, Guo J, Ye XY, Xie Y, Xie T. Oxidative stress: the core pathogenesis and mechanism of Alzheimer’s disease. Ageing Res Rev. 2022;77:101619. doi:10.1016/j.arr.2022.101619
   PubMed Web of Science ®Google Scholar
• Ionescu-Tucker A, Cotman CW. Emerging roles of oxidative stress in brain aging and Alzheimer’s disease. Neurobiol Aging. 2021;107:86–95. doi:10.1016/j.neurobiolaging.2021.07.014
   PubMed Web of Science ®Google Scholar
• Zhang W, Feng C, Jiang H. Novel target for treating Alzheimer’s diseases: crosstalk between the Nrf2 pathway and autophagy. Ageing Res Rev. 2021;65:101207. doi:10.1016/j.arr.2020.101207
   PubMed Web of Science ®Google Scholar
• Zhong G, Long H, Zhou T, et al. Blood-brain barrier Permeable nanoparticles for Alzheimer’s disease treatment by selective mitophagy of microglia. Biomaterials. 2022;288:121690. doi:10.1016/j.biomaterials.2022.121690
   PubMed Web of Science ®Google Scholar
• Furtado D, Björnmalm M, Ayton S, Bush AI, Kempe K, Caruso F. Overcoming the blood-brain barrier: the role of nanomaterials in treating neurological diseases. Adv Mater. 2018;30(46):e1801362. doi:10.1002/adma.201801362
   PubMed Web of Science ®Google Scholar
• Wong KH, Riaz MK, Xie Y, et al. Review of current strategies for delivering alzheimer’s disease drugs across the blood-brain barrier. Int J Mol Sci. 2019;20(2):381. doi:10.3390/ijms20020381
   PubMed Web of Science ®Google Scholar
• Zhang Q, Jeppesen DK, Higginbotham JN, et al. Supermeres are functional extracellular nanoparticles replete with disease biomarkers and therapeutic targets. Nat Cell Biol. 2021;23(12):1240–1254. doi:10.1038/s41556-021-00805-8
   PubMed Web of Science ®Google Scholar
• Bao Q, Hu P, Xu Y, et al. Simultaneous blood-brain barrier crossing and protection for stroke treatment based on edaravone-loaded ceria nanoparticles. ACS Nano. 2018;12(7):6794–6805. doi:10.1021/acsnano.8b01994
   PubMed Web of Science ®Google Scholar
• Naz S, Beach J, Heckert B, et al. Cerium oxide nanoparticles: a ‘radical’ approach to neurodegenerative disease treatment. Nanomedicine. 2017;12(5):545–553. doi:10.2217/nnm-2016-0399
   PubMed Web of Science ®Google Scholar
• Li X, Han Z, Wang T, et al. Cerium oxide nanoparticles with antioxidative neurorestoration for ischemic stroke. Biomaterials. 2022;291:121904. doi:10.1016/j.biomaterials.2022.121904
   PubMed Web of Science ®Google Scholar
• Ge K, Mu Y, Liu M, et al. Gold nanorods with spatial separation of CeO(2) deposition for plasmonic-enhanced antioxidant stress and photothermal therapy of Alzheimer’s disease. ACS Appl Mater Interfaces. 2022;14(3):3662–3674. doi:10.1021/acsami.1c17861
   PubMed Web of Science ®Google Scholar
• Zhang J, Cao Y, Wang CA, Ran R. Design and preparation of MnO2/CeO2-MnO2 double-shelled binary oxide hollow spheres and their application in CO oxidation. ACS Appl Mater Interfaces. 2016;8(13):8670–8677. doi:10.1021/acsami.6b00002
   PubMed Web of Science ®Google Scholar
• Atif M, Iqbal S, Fakhar-E-Alam M, et al. Manganese-doped cerium oxide nanocomposite as a therapeutic agent for MCF-7 adenocarcinoma cell line. Saudi J Biol Sci. 2021;28(2):1233–1238. doi:10.1016/j.sjbs.2020.12.006
   PubMed Web of Science ®Google Scholar
• Dai Y, Wang X, Zhu X, et al. Electrochemical assays for determination of H(2)O(2) and prostate-specific antigen based on a nanocomposite consisting of CeO(2) nanoparticle-decorated MnO(2) nanospheres. Mikrochim Acta. 2020;187(8):428. doi:10.1007/s00604-020-04403-7
   PubMed Web of Science ®Google Scholar
• Kim J, Kim HY, Song SY, et al. Synergistic oxygen generation and reactive oxygen species scavenging by manganese Ferrite/Ceria Co-decorated nanoparticles for rheumatoid arthritis treatment. ACS Nano. 2019;13(3):3206–3217. doi:10.1021/acsnano.8b08785
   PubMed Web of Science ®Google Scholar
• Gao J, Ma F, Wang X, Li G. Combination of dihydroartemisinin and resveratrol effectively inhibits cancer cell migration via regulation of the DLC1/TCTP/Cdc42 pathway. Food Funct. 2020;11(11):9573–9584. doi:10.1039/d0fo00996b
   PubMed Web of Science ®Google Scholar
• Huang DD, Shi G, Jiang Y, Yao C, Zhu C. A review on the potential of Resveratrol in prevention and therapy of diabetes and diabetic complications. Biomed Pharmacother. 2020;125:109767. doi:10.1016/j.biopha.2019.109767
   PubMed Web of Science ®Google Scholar
• Griñán-Ferré C, Bellver-Sanchis A, Izquierdo V, et al. The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer’s disease pathology: from antioxidant to epigenetic therapy. Ageing Res Rev. 2021;67:101271. doi:10.1016/j.arr.2021.101271
   PubMed Web of Science ®Google Scholar
• Moussa C, Hebron M, Huang X, et al. Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease. J Neuroinflammation. 2017;14(1):1. doi:10.1186/s12974-016-0779-0
   PubMed Web of Science ®Google Scholar
• Zhang W, Mehta A, Tong Z, Esser L, Voelcker NH. Development of polymeric nanoparticles for blood-brain barrier transfer-strategies and challenges. Adv Sci. 2021;8(10):2003937. doi:10.1002/advs.202003937
   Web of Science ®Google Scholar
• Rege SD, Geetha T, Griffin GD, Broderick TL, Babu JR. Neuroprotective effects of resveratrol in Alzheimer disease pathology. Front Aging Neurosci. 2014;6:218. doi:10.3389/fnagi.2014.00218
   PubMed Web of Science ®Google Scholar
• Aslam Saifi M, Hirawat R, Godugu C. Lactoferrin-decorated cerium oxide nanoparticles prevent renal injury and fibrosis. Biol Trace Elem Res. 2022;201(4):1837–1845. doi:10.1007/s12011-022-03284-6
   PubMed Web of Science ®Google Scholar
• Mazibuko Z, Choonara YE, Kumar P, et al. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders. J Pharm Sci. 2015;104(4):1213–1229. doi:10.1002/jps.24322
   PubMed Web of Science ®Google Scholar
• Tsatsanis A, McCorkindale AN, Wong BX, et al. The acute phase protein lactoferrin is a key feature of Alzheimer’s disease and predictor of Aβ burden through induction of APP amyloidogenic processing. Mol Psychiatry. 2021;26(10):5516–5531. doi:10.1038/s41380-021-01248-1
   PubMed Web of Science ®Google Scholar
• Mota I, De lima LS, Santana BM, et al. Alzheimer’s disease: innovative therapeutic approaches based on peptides and nanoparticles. Neuroscientist. 2023;29(1):78–96. doi:10.1177/10738584211016409
   PubMed Web of Science ®Google Scholar
• Yang X, Yang W, Xia X, et al. Intranasal delivery of BACE1 siRNA and rapamycin by dual targets modified nanoparticles for alzheimer’s disease therapy. Small. 2022;18(30):e2203182. doi:10.1002/smll.202203182
   PubMed Web of Science ®Google Scholar
• Forloni G, Balducci C, Perry G, Avila J, Tabaton M, Zhu X. Alzheimer’s disease, oligomers, and inflammation. J Alzheimers Dis. 2018;62(3):1261–1276. doi:10.3233/JAD-170819
   PubMed Web of Science ®Google Scholar
• Sung PS, Lin PY, Liu CH, Su HC, Tsai KJ. Neuroinflammation and neurogenesis in Alzheimer’s disease and potential therapeutic approaches. Int J Mol Sci. 2020;21(3):701. doi:10.3390/ijms21030701
   PubMed Web of Science ®Google Scholar
• Zhou J, Yu W, Zhang M, Tian X, Li Y, Lü Y. Imbalance of microglial TLR4/TREM2 in LPS-Treated APP/PS1 transgenic mice: a potential link between alzheimer’s disease and systemic inflammation. Neurochem Res. 2019;44(5):1138–1151. doi:10.1007/s11064-019-02748-x
   PubMed Web of Science ®Google Scholar
• Zhai Z, Huang Y, Zhang Y, Zhao L, Li W. Clinical research progress of small molecule compounds targeting Nrf2 for treating inflammation-related diseases. Antioxidants. 2022;11(8):1564. doi:10.3390/antiox11081564
   Web of Science ®Google Scholar
• Dal Magro R, Vitali A, Fagioli S, et al. Oxidative stress boosts the uptake of cerium oxide nanoparticles by changing brain endothelium microvilli pattern. Antioxidants. 2021;10(2):266. doi:10.3390/antiox10020266
   Web of Science ®Google Scholar
• Kahroba H, Ramezani B, Maadi H, Sadeghi MR, Jaberie H, Ramezani F. The role of Nrf2 in neural stem/progenitors cells: from maintaining stemness and self-renewal to promoting differentiation capability and facilitating therapeutic application in neurodegenerative disease. Ageing Res Rev. 2021;65:101211. doi:10.1016/j.arr.2020.101211
   PubMed Web of Science ®Google Scholar
• Li Y, Li Y, Wang H, Liu R. Yb(3+), Er(3+) codoped cerium oxide upconversion nanoparticles enhanced the enzyme like catalytic activity and antioxidative activity for Parkinson’s Disease treatment. ACS Appl Mater Interfaces. 2021;13(12):13968–13977. doi:10.1021/acsami.1c00157
   PubMed Web of Science ®Google Scholar
• Meng Q, Wang A, Hua H, et al. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer’s disease. Int J Nanomedicine. 2018;13:705–718. doi:10.2147/IJN.S151474
   PubMed Web of Science ®Google Scholar
• Fão L, Mota SI, Rego AC. Shaping the Nrf2-ARE-related pathways in Alzheimer’s and Parkinson’s diseases. Ageing Res Rev. 2019;54:100942. doi:10.1016/j.arr.2019.100942
   PubMed Web of Science ®Google Scholar
• Meng M, Zhang L, Ai D, Wu H, Peng W. β-Asarone ameliorates β-amyloid-induced neurotoxicity in PC12 cells by activating P13K/Akt/Nrf2 signaling pathway. Front Pharmacol. 2021;12:659955. doi:10.3389/fphar.2021.659955
   PubMed Web of Science ®Google Scholar
• Ma T, Tan MS, Yu JT, Tan L. Resveratrol as a therapeutic agent for Alzheimer’s disease. Biomed Res Int. 2014;2014:350516. doi:10.1155/2014/350516
   PubMed Web of Science ®Google Scholar
• Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019;14:5541–5554. doi:10.2147/IJN.S200490
   PubMed Web of Science ®Google Scholar